View Item 

Show simple item record

Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells
dc.contributor.authorSilva, Luan César
dc.contributor.authorBorgato, Gabriell Bonifácio
dc.contributor.authorWagner, Vivian Petersen
dc.contributor.authorMartins, Manoela Domingues
dc.contributor.authorRocha, Guilherme Zweig
dc.contributor.authorLopes, Márcio Ajudarte
dc.contributor.authorSantos-Silva, Alan Roger
dc.contributor.authorCastro Júnior, Gilberto
dc.contributor.authorKowalski, Luiz Paulo
dc.contributor.authorNor, Jacques E.
dc.contributor.authorSquarize, Cristiane H.
dc.contributor.authorCastilho, Rogerio Moraes
dc.contributor.authorVargas, Pablo Agustin
dc.date.accessioned2022-08-02T18:59:12Z
dc.date.available2023-08-02 14:59:09en
dc.date.available2022-08-02T18:59:12Z
dc.date.issued2022-07
dc.identifier.citationSilva, Luan César ; Borgato, Gabriell Bonifácio ; Wagner, Vivian Petersen; Martins, Manoela Domingues; Rocha, Guilherme Zweig; Lopes, Márcio Ajudarte ; Santos-Silva, Alan Roger ; Castro Júnior, Gilberto ; Kowalski, Luiz Paulo; Nor, Jacques E.; Squarize, Cristiane H.; Castilho, Rogerio Moraes; Vargas, Pablo Agustin (2022). "Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells." Journal of Oral Pathology & Medicine (6): 553-562.
dc.identifier.issn0904-2512
dc.identifier.issn1600-0714
dc.identifier.urihttps://hdl.handle.net/2027.42/173145
dc.description.abstractAimTo evaluate the potential use of Cephaeline as a therapeutic strategy to manage mucoepidermoid carcinomas (MEC) of the salivary glands.Material and MethodsUM-HMC-1, UM-HMC-2, and UM-HMC-3A MEC cell lines were used to establish the effects of Cephaeline over tumor viability determined by MTT assay. In vitro wound healing scratch assays were performed to address cellular migration while immunofluorescence staining for histone H3 lysine 9 (H3k9ac) was used to identify the acetylation status of tumor cells upon Cephaeline administration. The presence of cancer stem cells was evaluated by the identification of ALDH enzymatic activity by flow cytometry and through functional assays using in vitro tumorsphere formation.ResultsA single administration of Cephaeline resulted in reduced viability of MEC cells along with the halt on tumor growth and cellular migration potential. Administration of Cephaeline resulted in chromatin histone acetylation as judged by the increased levels of H3K9ac and disruption of tumorspheres formation. Interestingly, ALDH levels were increased in UM-HMC-1 and UM-HMC-3A cell lines, while UM-HMC-2 showed a reduced enzymatic activity.ConclusionCephaeline has shown anti-cancer properties in all MEC cell lines tested by regulating tumor cells’ viability, migration, proliferation, and disrupting the ability of cancer cells to generate tumorspheres.
dc.publisherWiley Periodicals, Inc.
dc.subject.othercancer stem cells
dc.subject.otherhead and neck tumors
dc.subject.othersalivary gland cancer
dc.subject.othertarget therapy
dc.subject.otherchemotherapy
dc.subject.otherepigenetic
dc.titleCephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173145/1/jop13252_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173145/2/jop13252.pdf
dc.identifier.doi10.1111/jop.13252
dc.identifier.sourceJournal of Oral Pathology & Medicine
dc.identifier.citedreferenceAdams A, Warner K, Pearson AT, et al. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget. 2015; 6: 26633 - 26650.
dc.identifier.citedreferenceVargas PA, Gerhard R, Araújo Filho VJ, et al. Salivary gland tumors in a Brazilian population: a retrospective study of 124 cases. Rev Hosp Clin Fac Med São Paulo. 2002; 57: 271 - 276.
dc.identifier.citedreferenceda Silva LP, Serpa MS, Viveiros SK, et al. Salivary gland tumors in a Brazilian population: a 20-year retrospective and multicentric study of 2292 cases. J Craniomaxillofac Surg. 2018; 46: 2227 - 2233.
dc.identifier.citedreferenceLopes MA, Cruz Perez DE, Abreu Alves F, et al. Clinicopathologic and immunohistochemical study of intraoral mucoepidermoid carcinoma. Otolaryngol Head Neck Surg. 2006; 134: 622 - 626.
dc.identifier.citedreferenceCoca-Pelaz A, Rodrigo J, Triantafyllou A, et al. Salivary mucoepidermoid carcinoma revisited. Eur Arch Otorhinolaryngol. 2015; 272: 799 - 819.
dc.identifier.citedreferenceLe JM, Squarize CH, Castilho RM. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells. 2014; 6: 511 - 525.
dc.identifier.citedreferenceWebber LP, Wagner VP, Curra M, et al. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. Histopathology. 2017; 71: 278 - 286.
dc.identifier.citedreferenceAlmeida LO, Abrahao AC, Rosselli-Murai LK, et al. NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 2013; 30: 96 - 104.
dc.identifier.citedreferenceGuimarães DM, Almeida LO, Martins MD. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget. 2016; 7: 42447 - 42460.
dc.identifier.citedreferenceAdorno-Cruz V, Kibria G, Liu X, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Can Res. 2015; 75: 924 - 929.
dc.identifier.citedreferenceWagner VP, Martins MA, Martins MD, et al. Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axis. Oncotarget. 2016; 7: 73032 - 73044.
dc.identifier.citedreferenceZhang J, Harvey SE, Cheng C. A high-throughput screen identifies small molecule modulators of alternative splicing by targeting RNA G-quadruplexes. Nucleic Acids Res. 2019; 47: 3667 - 3679.
dc.identifier.citedreferenceWagner VP, Martins MD, Martins MAT, et al. Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep. 2018; 8: 2065.
dc.identifier.citedreferenceYang S, Xu M, Lee E, et al. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov. 2018; 5: 31.
dc.identifier.citedreferenceWarner KA, Adams A, Bernardi L, et al. Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol. 2013; 49: 1059 - 1066.
dc.identifier.citedreferenceGlozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26: 5420 - 5432.
dc.identifier.citedreferenceMarkman RL, Webber LP, Nascimento Filho CHV, et al. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma. Cell Oncol. 2019; 42: 143 - 155.
dc.identifier.citedreferenceParag-Sharma K, Tasoulas J, Musicant AM, et al. Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma. Oral Oncol. 2021; 115: 105166.
dc.identifier.citedreferenceCreagan ET, Woods JE, Rubin J, et al. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988; 62: 2313 - 2319.
dc.identifier.citedreferenceLicitra L, Marchini S, Spinazzè S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991; 68: 1874 - 1877.
dc.identifier.citedreferenceGilbert J, Li Y, Pinto H, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006; 28: 197 - 204.
dc.identifier.citedreferenceSebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat. 2011; 10: 128 - 134.
dc.identifier.citedreferenceGoetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018; 109: 952 - 963.
dc.identifier.citedreferenceYosifov DY, Idler I, Bhattacharya N, et al. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia. 2020; 34: 115 - 127.
dc.identifier.citedreferenceFares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther. 2020; 5: 28.
dc.identifier.citedreferenceHalkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004; 59: 177 - 189.
dc.identifier.citedreferenceHrzenjak A, Moinfar F, Kremser ML, et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 2006; 5: 2203 - 2210.
dc.identifier.citedreferenceSong J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005; 13: 264 - 268.
dc.identifier.citedreferenceAlmeida LO, Guimarães DM, Squarize CH, et al. Profiling the behavior of distinct populations of head and neck cancer stem cells. Cancers (Basel). 2016; 8: 7.
dc.identifier.citedreferenceGiudice FS, Pinto DS Jr, Nör JE, et al. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 2013; 8: e58672.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jop13252_am.pdf
Size:
582.7KB
Format:
PDF
View/Open
Name:
jop13252.pdf
Size:
16.53MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.